Boehringer Ingelheim BioXcellence™ and Sutro Biopharma Inc.today announced that they successfully applied Sutro’ ...

Sutro Biopharma's valuation remains compelling despite recent market hits, with optimism for a turnaround. Click here to find ...

Boehringer Ingelheim BioXcellence and Sutro Biopharma (STRO) announced that they successfully applied Sutro’s proprietary cell-free expression ...

Sutro Biopharma, Inc. (NASDAQ:STRO – Get Free Report) saw a significant growth in short interest during the month of December. As of December 15th, there was short interest totalling 2,460,000 shares, ...

A look at the shareholders of Sutro Biopharma, Inc. (NASDAQ:STRO) can tell us which group is most powerful. With 69% stake, institutions possess the maximum shares in the company. In other words ...

Luveltamab tazevibulin is under clinical development by Sutro Biopharma and currently in Phase II for Non-Small Cell Lung Cancer.

Sustainalytics’ Controversies Research identifies companies involved in incidents and events that may negatively impact stakeholders, the environment or the company’s operations. Controversies ...

Why was Mount Sutro Open Space Reserve Vegetation Management Plan needed? California’s multi-year drought and other factors caused significant decline in tree health, threatening both public safety ...

Sutro Biopharma, Inc. (STRO) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.74. This compares to loss of $0.81 per share a year ago.

Ingelheim, Germany Thursday, January 9, 2025, 15:00 Hrs [IST] ...